Japan’s Ministry of Health, Labor and Welfare approves Astellas Pharma’s (OTCPK:ALPMF) Xtandi (enzalutamide) for the treatment of prostate cancer patients with distant metastases.
Previously, it was approved for castration-resistant prostate cancer.
The company has global ex-U.S. rights to the androgen receptor inhibitor under an agreement with Pfizer’s (NYSE:PFE) Medivation. The parties have co-commercialization rights in the U.S.
https://seekingalpha.com/news/3578583-astellas-xtandi-okd-in-japan-for-new-prostate-cancer-indication
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.